Leapmotor Debuts Global Product C10 and New Technologies at Munich, Launches Global Strategy
5.9.2023 20:27:00 EEST | Business Wire | Press release
On September 4th, Leapmotor made its debut at the IAA MOBILITY 2023 (hereinafter referred to as "Munich Motor Show"), where the "LEAP TOGETHER: Shaping a Shared Technological Future" global press conference was held. The event comprehensively showcased the latest achievement of all-domain in-house development, Leap 3.0 architecture, and the inaugural global model, the C10.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905065907/en/
C10 Model (Photo: Business Wire)
Leapmotor's Founder, Chairman, and CEO, Zhu Jiangming, emphasizes, “Leapmotor's globalization strategy encompasses the internationalization of both products and technology. Over 8 years of all-domain in-house development, Leapmotor has evolved from LEAP1.0 to LEAP3.0. With the arrival of our first global product based on LEAP3.0 architecture, the C10, all of Leapmotor's subsequent products will be designed and developed with a global mindset and adhere to global standards. In the next 2 years, Leapmotor will introduce 5 globally-oriented products in Europe, Asia-Pacific, the Middle East, the Americas, and other regions, offering intelligent mobility experiences to automotive consumers worldwide.”
As a technology-driven intelligent electric vehicle enterprise, Leapmotor remains steadfast in its commitment to all-domain in-house development of core technologies. With an unwavering commitment to shaping a shared future of intelligent mobility, Leapmotor remains devoted to delivering the finest smart mobility experience to all consumers.
Eight Years of All-domain In-house Development, LEAP 3.0 Embodies Cutting-Edge Intelligent Electric Technologies
Leap 3.0, with a central integrated electronic and electrical architecture as its core, encompasses several leading technologies, including CTC 2.0 (Cell-to-Chasis) technology, a latest oil-cooling electric drive, the intelligent cockpit with a Qualcomm Snapdragon 8295 chip, and a leading intelligent driving system. It is also built to global standards, and boasts an 88% interchangeability, imbuing each product with inherent intelligence, comfort, and safety traits.
Leapmotor's [Four-Leaf Clover] central integrated E/E architecture employs a central supercomputing platform, which seamlessly integrates the cockpit domain, pilot domain, power domain, and vehicle body domain, realizing the industry's pioneering convergence of these four domains. Furthermore, it enables vehicle-level seamless over-the-air (OTA) updates for five years. With over 500 reserved interfaces, it ensures Leapmotor to deliver an evolving and personalized driving experience.
Following last year's release of the package-less CTC technology, Leapmotor takes it a step further with CTC 2.0. This advanced technology eliminates modules, incorporates new safety features, and integrates a Battery Management System (BMS). This highly integrated battery-chassis equips the vehicle with attributes of extended range, enhanced safety, superior performance, and accelerated energy replenishment.
The latest oil-cooling electric drive features innovations that span from mid-voltage flat wire technology to high-voltage silicon carbide technology, offering power outputs ranging from 170kW to 250kW to accommodate both rear-wheel drive and all-wheel drive applications. The incorporation of high-voltage silicon carbide technology into the flat wire oil-cooling electric drive achieves a comprehensive efficiency of 92%, all while weighing only 76kg. This results in an ultra-compact and exceptionally powerful solution.
The Leapmotor intelligent cockpit system maximizes the capabilities of a Qualcomm Snapdragon 8295 chip, bestowing the cockpit with robust computing power and a seamless customer experience. The newly developed Leap OS intelligent desktop operating system caters to a multitude of driving scenarios, allowing customizable settings to accommodate diverse usage patterns.
At the intelligent driving level, the vehicle with Leap 3.0 is equipped with 30 high-performance perception hardware components, including LiDAR and an 8 million-pixel HD camera, delivering enhanced precision in perception. It is powered by an NVIDIA DRIVE Orin system-on-a-chip (SoC), which delivers 254 TOPS of computing to enable safe, high-speed and urban NAP intelligent-driving capabilities.
As an all-encompassing solution for intelligent electric vehicle technology, LEAP 3.0 stands as a prominent global leader in the field of intelligent electric vehicle technologies.
Leapmotor Initiates Globalization Strategy through Product Innovation and Technological Advancements
Leapmotor unveils C10 as the first model under LEAP3.0 architecture, marking its inaugural global strategic model. Embracing the signature design language of the Leapmotor family and leveraging the latest innovations of LEAP3.0, C10 embarks on an intelligent evolution to shape the future of mobility.
During the press conference, Mr. Zhu Jiangming stated, "Openness, co-creation, and global collaboration are key to achieving rapid proliferation of intelligent electric vehicles. Looking ahead, Leapmotor is not only an automobile manufacturer but also a comprehensive provider of intelligent electric vehicle solutions."
Globally, Leapmotor offers four different technology cooperation models, ranging from scratch to completion. Additionally, Leapmotor actively engages in strategic partnerships with world-renowned mobility ecosystem partners such as NVIDIA, ZF, Qualcomm, Bosch, and NXP.
The initiation of the global strategy is a critical step for Leapmotor as it leads the way with its competence of all-domain in-house development, driving the company's upward trajectory. It is also a demonstration of the synergy between brand strength, technological prowess, and influence.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905065907/en/
Contact information
Tammy Hu
hu_huiling@leapmotor.com
Lexi Liu
liu_xinyun@leapmotor.com
+86 15601869865
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom